Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 31ST DECEMBER 2014
PART - I

S.	Particulars	QUARTER ENDED			HALF YEAR ENDED		Rs. in Lakhs) YEAR ENDED
No.		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
				Un-audited			Audited
1	Income from Operations						
	(a)Net Sales/Income from operations	50.61	45.29		141.10	44.58	140.52
	(b)Other Operating Income	0.00			0.00	0.00	0.00
	Total Income from Operations	50.61	45.29	28.38	141.10	44.58	140.52
2	Expenses						
	a. Consumption of raw materials	3.02	1.55		7.49		0.00
	b. Purchases of stock-in-trade	39.37	25.14	18.72	85.76	29.93	103.94
	c. Increase/decrease in stock in trade and WIP	(15.00)	3.03		(14.06)		(5.52
	d. Power & Fuel	0.00	0.00				0.00
	e. Sales Tax and other Taxes	0.00	0.00		0.00		0.00
	f Employees Cost	5.65	4.87	2.54	14.95		9.55
	g. Depreciation	1.68	1.68				8.00
	h. Other expenditure	14.09	11.65		48.55		76.18
	Total	48.81	47.92	28.39	147.73	54.93	192.15
	(Any item exceeding 10% of the total expenditure to be shown separetely)	0.00	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other Income, finance costs and Exceptional Items (1-2)	1.80	(2.63)	(0.01)	(6.63)	(10.35)	(51.63)
4	Other Income	0.04	4.95	3.03	12.42	0.95	15.84
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional	1.84		3.02	5.79		(35.79)
	items						
6	Finance Cost	0.00	0.00	0.17	0.00	0.17	0.81
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	1.84	2.32	2.85	5.79	(9.57)	(36.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities	1.84	2.32	2.85	5.79	(9.57)	(36.60)
10	Tax expense						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	(1.17)
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+)/ Loss (-) from ordinary activities after tax	1.84	2.32	2.85	5.78	(9.57)	(35.43)
12	Extraordinary items (net of tax expense Rs.Nil)	Nil	Nil	Nil	Nil	Nil	Ni
13	Net Profit (+)/Loss (-) for the period	1.84	2.32	2.85	5.78	(9.57)	(35.43)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.94	9.94	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extraordinary items - not annualised)						
	a) Basic	0.05	0.07	0.08	0.17	-0.28	(1.04)
	b) Diluted	0.05	0.07	0.08	0.17	-0.28	(1.04)

17		ings Per Share (after aordinary items - not annualised)						
	a)	Basic	0.05	0.07	0.08	0.17	-0.28	(1.04)
	b)	Diluted	0.05	0.07	0.08	0.17	-0.28	(1.04)
PAR	T - II							
		ulars of Shareholding						
1	Public shareholding							
		- Number of shares	3148711	3174393	3166405	3148711	3166405	3166405
	- Percentage of shareholding		92.46%	93.21%	92.98%	92.46%	92.98%	92.98%
2	Promoters and Promoter Group							
	Shareholding							
	a	Pledged/Encumbered - No. of	NIL	NIL	NIL	NIL	NIL	NIL
		percentage of shares	NIL	NIL	NIL	NIL	NIL	NIL
		(as a % of the total shareholding of						
		promoter and promoter group)						
		percentage of shares	NIL	NIL	NIL	NIL	NIL	NIL
		(as a % of the total share capital of						
	b	Non - encumbered						
		Number of shares	256789	231107	239095	256789	239095	239095
		percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
		percentage of shares (as a % of the total sharecapital of the company)	7.54%	6.79%	7.02%	7.54%	7.02%	7.02%
B.	Particulars			3 monthsended 31/12/2014				
	INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter				Nil			
	Received during the quarter				Nil			
	Disposed of during the quarter				Nil			
	Remaining unresolved at the end of the quarter				N	l .		

Notes:

- 1 The above results have been reviewed by the Audit Committee and taken on by the Board at its Meeting held on 14th day
- Figures for the previous Year/Quarter/ Half yearly have been rearranged / regrouped wherever necessary.
 The Company's exclusive business is manufacturing and selling of Drugs Formulation and as such this is the only reportable segment as per Accounting Standard 17 on segment reporting issued by the ICAI
- Provisions for Income Tax and Differed Tax will be made at the end of the Financial Year

 During this quarter the Company has adopted the useful life of Fixed assets as indicated in Schedule II of Companies Act 2013 effective from 1st April 2014, as result the depreciation charge for the half year ended December 31, 2014 is higher by Rs.1.02 lakhs. Carrying value of assets amounting to Rs.3.36 lakhs which has completed its useful life period as on 01.04.2014 is adjusted against the accumulated balance of Retained earnings (deficit).

For PHARMAIDS PHARMACEUTICALS LIMITED

PLACE: HYDERABAD DATE: 14.02.2015

Dr. Ghisulal Jain Chairman & Managing Director



14-6-191, Nagar Khana, Begum Bazar, HYDERABAD - 500 012. (A.P.) INDIA E-mail: rsjainassociates@rediffmail.com Phone: 040-24614481, Fax: 040-24617420 Suresh Kumar Jain (Mob): +91-9849025612 B. Ramesh Kumar (Mob): +91-9849025641

Date

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of un-audited standalone financial results of PHARMAIDS PHARMACEUTICALS LIMITED ("the Company") for the quarter ended 31st December, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter Group Shareholding' which has been traced from disclosures made by the management and has not been audited by us. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an opinion. We have not performed an audit and accordingly we do not express such an opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end. Attention is drawn towards Note no.5 relating to accounting of Depreciation as per Schedule II to the Companies Act, 2013.

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section Rules, 2014, and other recognized accounting policies and practices generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RAKESH S JAIN & ASSOCIATES Chartered Accountants Firm Reg No. 010129S

Date:14.02.2015 Place: Hyderabad. (B.RAMESH KUMAR)
Partner
M. No. 200304